CYP2C19 Genotyping and Antiplatelet Therapy

Current Guideline Recommendations

The American College of Cardiology and American Heart Association (ACC/AHA) guidelines do not recommend routine CYP2C19 genotyping in patients undergoing percutaneous coronary intervention (PCI) due to lack of prospective evidence demonstrating improved outcomes with genotype-guided therapy 1, 2
The ACC/AHA and Society for Cardiovascular Angiography and Interventions (SCAI) guidelines explicitly state that routine clinical use of CYP2C19 genotyping is not recommended due to the absence of prospective clinical evidence showing that changing antiplatelet therapy based on genotype improves outcomes 2
The FDA issued a black box warning advising practitioners to consider alternative treatment in CYP2C19 poor metabolizers, but this warning does not mandate testing 1, 3, 4
The 2011 ACC/AHA guidelines note that genetic test kits are commercially available, but expensive, not routinely covered by insurance, and no prospective studies demonstrate that routine genotyping coupled with therapy modification improves clinical outcomes 5

Ticagrelor is an active compound requiring no biotransformation, while clopidogrel is a prodrug requiring CYP2C19 metabolism 6
Ticagrelor shows less variability in response compared to clopidogrel, and the impact of genotype and concomitant medications is minimal 6
Clinical utility of genotyping is not rigorously established but less likely to be necessary for ticagrelor given the lesser degree of variation in response 6

Patients of Asian descent, where CYP2C19 loss-of-function alleles are most prevalent (31% carry 2 allele, and 3 allele is more common than in other populations), may benefit from genotyping on a case-by-case basis 1
Patients who have experienced recurrent acute coronary syndrome (ACS) events despite ongoing clopidogrel therapy in the past may benefit from genotyping 5
Patients undergoing high-risk PCI where maximizing efficacy is critical may benefit from genotyping 5

If switching from ticagrelor to clopidogrel without genotyping, ensure the patient understands they are moving from a more potent, genotype-independent antiplatelet agent to one with variable response 6
Continue aspirin 75-100mg daily as part of dual antiplatelet therapy 6, 7
Maintain clopidogrel 75mg daily for the full recommended duration (minimum 12 months for drug-eluting stents) 6, 7
Monitor closely for any signs of myocardial ischemia, including chest pain, dyspnea, or anginal equivalents 7

If genotyping is performed and reveals CYP2C19 loss-of-function alleles (2 or 3), consider returning to ticagrelor or switching to prasugrel (if no contraindications) 6
Carriers of one or two CYP2C19 loss-of-function alleles have significantly reduced active metabolite levels, high on-treatment platelet reactivity, and increased risk of major adverse cardiovascular events 3, 4, 8